Colombia Confirms First Mpox Clade Ib Case: Symptoms and Facts

Colombia has confirmed its first case of a new variant of mpox, specifically clade Ib, marking a significant development in the country’s ongoing surveillance of the virus. The case was identified in the Antioquia department and officially verified by the Ministry of Health and Social Protection (MinSalud) in mid-April 2026. This detection follows increased monitoring efforts across Latin America after the World Health Organization (WHO) highlighted the emergence of clade Ib as a variant of concern due to its potential for increased transmissibility and distinct clinical presentation compared to earlier strains.

According to official statements from MinSalud, the patient is an adult male who presented with symptoms consistent with mpox but exhibited atypical features that prompted further laboratory testing. Genetic sequencing conducted at the National Institute of Health confirmed the infection was caused by the monkeypox virus belonging to clade Ib, a lineage first identified in the Democratic Republic of the Congo and later detected in several other countries through international travel-linked cases. Health authorities emphasized that the individual had no recent history of international travel, suggesting possible local transmission, although investigations are ongoing to determine the exact source of exposure.

The confirmation was first reported by Colombian media outlets including El Tiempo, El Espectador, and Caracol Radio, all of which cited MinSalud’s official announcement. Subsequent reporting by La FM provided additional detail, noting that the case was identified in the municipality of Envigado, within the Antioquia metropolitan area. Contact tracing efforts were immediately initiated, and close contacts of the patient are being monitored for symptom development. As of the latest update, no secondary cases have been confirmed linked to this initial infection.

Mpox, formerly known as monkeypox, is a viral zoonotic disease caused by the monkeypox virus, which belongs to the Orthopoxvirus genus. While historically endemic in parts of Central and West Africa, the virus gained global attention in 2022 when a widespread outbreak affected numerous countries outside the continent, primarily through close personal contact. The virus is divided into two main clades: clade I, which includes subtypes Ia and Ib and is generally associated with more severe disease, and clade II, which was responsible for the 2022 global outbreak and tends to cause milder symptoms.

Clade Ib, in particular, has drawn increased scrutiny from global health experts due to reports suggesting it may be associated with higher rates of human-to-human transmission and potentially more pronounced clinical manifestations, although data remain limited. Symptoms of mpox typically include fever, headache, muscle aches, fatigue, and swollen lymph nodes, followed by the development of a characteristic rash that progresses through stages—from macules to papules, vesicles, pustules, and finally scabs. The rash often appears on the face, palms, soles, and genital or perianal areas, though distribution can vary.

In this Colombian case, health officials noted that while the patient presented with fever and lymphadenopathy, the rash exhibited some atypical features that initially complicated clinical diagnosis. This underscores the importance of maintaining a high index of suspicion and utilizing polymerase chain reaction (PCR) testing for accurate identification, especially when dealing with emerging variants that may not present with textbook symptoms. MinSalud reiterated that laboratory confirmation remains the gold standard for diagnosing mpox, regardless of clinical presentation.

Transmission of the monkeypox virus occurs primarily through close contact with infectious lesions, bodily fluids, or respiratory droplets, as well as through contaminated materials such as bedding or clothing. While airborne transmission over long distances is not considered a significant route, prolonged face-to-face interaction increases risk. The virus can also be transmitted from animals to humans, though no animal reservoir has been identified in Colombia to date. Public health messaging continues to emphasize avoiding skin-to-skin contact with individuals showing unexplained rashes or lesions and practicing good hand hygiene.

Vaccination remains a key preventive tool, particularly for individuals at higher risk of exposure. The modified vaccinia Ankara (Bavarian Nordic) vaccine, marketed as JYNNEOS or Imvamune, has shown effectiveness against both clade I and clade II strains and is recommended for pre-exposure prophylaxis in high-risk groups and post-exposure protection within four days of contact. Colombia has maintained a strategic reserve of vaccines since the 2022 outbreak and has indicated readiness to deploy them if deemed necessary based on risk assessment.

Health authorities in Colombia have not declared any changes to public risk levels at this time, stating that the detection of a single case does not indicate widespread community transmission. However, they have urged healthcare providers to remain vigilant, particularly in urban centers with high mobility and connectivity. Surveillance systems have been strengthened in recent months, with expanded testing capacity and improved reporting protocols designed to detect atypical or emerging variants quickly.

The identification of clade Ib in Colombia adds the country to a growing list of nations where this variant has been detected, including cases linked to travel in Europe and North America. While the global risk posed by clade Ib is still under evaluation, the WHO continues to monitor the situation closely and has called for increased genomic surveillance to better understand the variant’s behavior, transmission dynamics, and potential impact on public health interventions.

For now, the focus remains on containment, contact tracing, and public awareness. Officials stress that while the situation warrants attention, there is no cause for alarm. The general public is advised to stay informed through official channels, seek medical care if unexplained symptoms develop, and avoid stigmatizing individuals affected by the virus. As research evolves, Colombia’s health institutions affirm their commitment to adapting responses based on the best available scientific evidence.